Safety and Efficacy of Using Orismilast for the Treatment of Patients With Mild to Severe Hidradenitis Suppurativa
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of the European Academy of Dermatology and Venereology: JEADV
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Orismilast for the treatment of mild to severe hidradenitis suppurativa: Week 16 data from OSIRIS, a Phase 2a, open-label, single-centre, single-arm, dose-finding clinical trial
J Eur Acad Dermatol Venereol 2023 Dec 26;[EPub Ahead of Print], CG Frederiksen, FB Sedeh, EH Taudorf, DM Saunte, GBE JemecFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.